SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00897091

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Molecular Predictors of Outcome on CAF Plus Tamoxifen Versus Tamoxifen Alone in Postmenopausal Women With Node Positive, Receptor Positive Breast Cancer [NCI Correlative Science Reference No. # 8814A-ICSC]

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in predicting outcome in postmenopausal women with hormone receptor-positive, node-positive breast cancer treated with tamoxifen with or without cyclophosphamide, doxorubicin, and fluorouracil.

NCT00897091 Breast Cancer
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

4 Interventions

Name: comparative genomic hybridization

Type: Genetic

Name: microarray analysis

Type: Genetic

Name: reverse transcriptase-polymerase chain reaction

Type: Genetic

Name: diagnostic laboratory biomarker analysis

Type: Other


Primary Outcomes

Measure: Disease-free survival

Measure: Overall survival

Secondary Outcomes

Measure: Distant disease-free recurrence

Time Perspective: Retrospective


There is one SNP

SNPs


1 S8814A

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. --- S8814A ---



HPO Nodes


HPO: